Low-dose naltrexone (LDN) has been identified as a potential treatment for Long COVID after a Griffith University study, ...

A surgical implant that reduces cravings for alcohol is helping free patients and their families from the pain of addiction.

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Low-dose naltrexone, a medication typically used for treating opioid addiction, has been identified as a potential treatment ...

Low-dose naltrexone (LDN) has been identified as a potential treatment for Long COVID after a ground-breaking Griffith University study found it ...

Naloxone (Narcan), naltrexone (Trexan; ReVia), and Vivitrol (long-acting injectable naltrexone) changed addiction medicine into a profession with FDA-approved treatments for opioid overdose reversal, ...

BioCorRx Pharmaceuticals Inc. Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, from USWM, LLC ANAHEIM, CA - May 20, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) ...

ReVia), and Vivitrol (long-acting injectable naltrexone) changed addiction medicine into a profession with FDA-approved treatments for opioid overdose reversal, opioid use disorder (OUD), and ...

Alas, not all the news is good. While the number of fatal overdoses is down, the number of overall overdoses is increasing ...

Daily oral and monthly extended-release injectable naltrexone were similarly effective at reducing heavy drinking days in patients with alcohol use disorder (AUD), a hospital-based randomized ...

The pellets gradually release naltrexone hydrochloride, a medication that suppresses psychological cravings in alcohol-dependent individuals and reduces the risk of relapse. The patient ...